insights_auto
Why is BT3 up 8,66%?
Dive Deeperchevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
€0,89
arrow_upward
+8,66%(+0,071) 1D
9 ຕ.ລ., 22 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BT3...
Open
€0,89
High
€0,89
Low
€0,89
Mkt. cap
251,39 ລ້ານ
Avg. vol.
37,00
Volume
0,00
52-wk high
€1,69
52-wk low
€0,78
No. of employees
75
Open
€0,89
High
€0,89
Low
€0,89
Mkt. cap
251,39 ລ້ານ
Avg. vol.
37,00
Volume
0,00
52-wk high
€1,69
52-wk low
€0,78
No. of employees
75
News stories
From web sources and news partners
Benzinga
·
1 ຊົ່ວໂມງກ່ອນ
S&P 500 Earnings Preview: Will Strong Profits Fuel the Next Rally?
The Globe and Mail
·
1 ຊົ່ວໂມງກ່ອນ
Lunai Bioworks Seeks Nasdaq Trading Suspension Amid Probe
The Globe and Mail
·
1 ຊົ່ວໂມງກ່ອນ
The Nasdaq-100 Has Gained 20% or More 3 Years Running. This Streak Rests on Far Stronger Earnings Than 1999's.
Yahoo Finance
·
2 ຊົ່ວໂມງກ່ອນ
Dell (DELL) Has Outpaced the S&P 500 by a Wide Stretch. Will the AI-Fueled Run Continue?
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc